CrystalGenomics Inc (083790) Fair Value & Analysis
Healthcare · KR · Market cap 63.8B KRW
Fair value as of: Aug 13, 2026
From 3 valuation models · updated 6 days ago
Fair value updated Aug 13, 2026, revised from 786.54 KRW to 697.28 KRW (−11.3%) since Jul 22, 2026. Share price −0.1% over the past month.
Below-average quality, and screening another 17% overvalued on our models.
What matters now
- Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The model range is unusually wide (317.20 KRW to 1,184 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range 744.00 KRW – 10,067 KRW · fair‑value band 317.20 KRW – 1,184 KRW · the 845.00 KRW price screens above the 697.28 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
CrystalGenomics Inc (083790) currently trades at 845.00 KRW, while our model-based Fair Value estimate is 697.28 KRW, implying the stock looks roughly 17.5% overvalued today. The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, CrystalGenomics Inc generated revenue of 45.0B KRW at a net margin of -64.6%. Revenue declined 0.8% year over year. Net debt stands at 32.5B KRW. Fundamentals as of Aug 13, 2026
Our scenario range runs from 317.20 KRW (bear case) to 1,184 KRW (bull case); at 845.00 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 58% below its 52-week high and 11% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 12% fair-value upside, at -17%, 083790 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 3 models by family
Widest divergence: Asset-Based (916.22 KRW) versus Dividend Discount (527.57 KRW). Highest evidence: Gordon GGM (70).
Notify me when 083790 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 43 · Market factors (momentum, volatility) 18
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial.
Full company description
CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histone deacetylase inhibitor for cancer, which is in Phase I clinical trial; and CG400549, an antibiotic candidate for methicillin resistant staphylococcus aureus and vancomycin resistant staphylococcus aureus, which is in Phase I clinical trial. In addition, it offers cloning, expression, purification, and characterization of proteins of interest; and assay and structure services. The company has drug discovery collaborations with AstraZeneca, Daiichi-Sankyo, SBI-Biotech, Carna Biosciences, Yuyu Pharma, AmorePacific, Hanmi Pharmaceuticals, and ProQuest Investments. CrystalGenomics, Inc. was founded in 2000 and is headquartered in Seongnam, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
CrystalGenomics Inc reported revenue of 27.4B KRW in FY2025 versus 42.4B KRW in FY2021, a compound −10.3%/yr. Reported net income was −3.5B KRW in FY2025.
083790 screens 17% overvalued. Compare with Torrent Pharmaceuticals Limited →
Peer Group
Pharmaceuticals · 25 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Torrent Pharmaceuticals Limited 500420 | ₹4,876 | ₹4,360 | -11% |
| GlaxoSmithKline Pharmaceuticals Limited 500660 | ₹2,620 | ₹1,452 | -45% |
| Caregen Co 214370 | 64,400 KRW | 7,277 KRW | -89% |
| ST Pharm Co 237690 | 107,000 KRW | 50,110 KRW | -53% |
| 524816 524816 | ₹889.70 | ₹1,388 | +56% |
| Oscotec Inc 039200 | 38,800 KRW | 33,210 KRW | -14% |
| DongKook Pharmaceutical Co 086450 | 21,600 KRW | 31,283 KRW | +45% |
| 532300 532300 | ₹1,894 | ₹2,120 | +12% |
| Kolon Life Science Inc 102940 | 17,460 KRW | 37,129 KRW | +113% |
| Huons Global Co 084110 | 23,200 KRW | 58,482 KRW | +152% |
Compare CrystalGenomics Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is CrystalGenomics Inc (083790) overvalued or undervalued?
What is the fair value of 083790?
What is the quality score of 083790?
What is the revenue of CrystalGenomics Inc (083790)?
What is the net profit margin of 083790?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track CrystalGenomics Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.